Labcorp Holdings Inc.

LH Healthcare Diagnostics & Research

Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.

Revenue
+6.92%
EPS
+3.32%
Free cash flow
+44.7%
Total debt
+3.21%

Quarter to September 2026, against a year earlier

366.08 2.78 +0.77%
Market cap
$29.5B
P/E
29.8×
Fwd P/E
26.7×
Dividend yield
0.79%
F-score
8/9
Altman Z
3.02
Beneish M
−2.55
Dividend safety
74/100

Labcorp Holdings Inc. 10-Q filed Aug 1, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 1:25 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 29, 2025: 17 added · 10 removed · 32 modified; 6 with only figures updated

  1. Modified · FORWARD-LOOKING STATEMENTS

    9.changes in and failure to comply with the applicable regulations of pharmaceutical and medical device regulators affecting the approval, availability of, and the selling and marketing of diagnostic tests, including LDTs, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S. Food and Drug Administration (FDA), the U.S. Department of Agriculture, the Medicine